$WEYL Q3 2019 Highlights Revenue, comprised of recurring

New Post Public Reply Private Reply Replies (0) Message Board
Lets Roll
212
$WEYL Q3 2019 Highlights

Revenue, comprised of recurring subscription fees, totaled a record $9.0 million, up 26% from the previous quarter and up 7% from the year-ago quarter.
Net loss improved 35% from the previous quarter and 46% from the year-ago quarter to a loss of $1.1 million or $(0.01) per share.
Turned adjusted EBITDA positive during the final month of the quarter (see definition of this non-GAAP term, below.)
Increased adoption of the company’s CreateApp mobile app solution for SMBs, which included new customers as well as existing customers subscribing to additional features and modules.
Partnered in the launch of AtozGo™, a short distance food delivery service in Jakarta, Indonesia, followed by joining forces with Grab, the leading online-to-offline mobile platform in Southeast Asia, to market the service. AtozGo addresses the need for a hyper-local, pedestrian-powered food delivery service that can make food delivery from local establishments quick and easy for office workers and urbanites. In three months since launch, lunchtime deliveries have scaled to more than 10,000 per day for 35,000 customers.
Appointed Sim Farar and Andre Peschong to the company’s advisory board. Farar’s 30 years of experience in both public and private sectors, along with Peschong’s more than 25 years of senior management and capital markets experience, will provide the board with important insights and guidance as it pursues its plans for organic and acquisitive growth.
Raised gross proceeds of approximately $6.4 million In a private placement offering.
Cash and cash equivalents totaled $5.8 million at September 30, 2019.
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Hims & Hers Health Faces Revenue Challenges and Legal Issues

Updated Category News Views 246

Hims & Hers Revenue Challenges Amid Stock Decline In recent trading sessions, Hims & Hers Health reported notable stock fluctuations as the company unveiled a decline in revenue per customer linked to its customization of GLP-1 medications for weight loss. This announcement caused an almost 11% drop in the stock price. Impacts of Collaboration Termination This steep...

Continue Reading
Entrée Resources Reports Solid Results for Q3 2025

Updated Category News Views 166

Entrée Resources Ltd. Overview Entrée Resources Ltd. (TSX: ETG; OTCQB: ERLFF), a reputable Canadian mining company focused on the Oyu Tolgoi project, has announced its interim financial results for the third quarter of 2025. This announcement sheds light on its ongoing operations and future plans, emphasizing the company's significant role in one of the world's largest...

Continue Reading
Bucket List Wine Dinners Beckon to Los Angeles

Updated Category News Views 10

Sipping on the Extraordinary: LA Wine Soiree When was the last time you had a glass of wine that truly feels like you've unlocked a treasure chest? That's what LearnAboutWine.com is going for with their bucket list wine dinners in Los Angeles. Imagine tasting some of the world's most coveted bottles, all served with a level of polish that screams high-end dining. Led by...

Continue Reading
BioLife Solutions Enhances Growth Potential with $73 Million Sale

Updated Category News Views 68

BioLife Solutions Announces $73 Million Sale of SciSafe In a significant move aimed at reinforcing its strategic direction, BioLife Solutions, Inc. (NASDAQ: BLFS), a prominent player in the development and supply of cell processing tools and services for the cell and gene therapy market, has announced the sale of its biostorage subsidiary, SciSafe Holdings, Inc. The...

Continue Reading
Advancements in Universal Vaccine Development by Dx&Vx

Updated Category News Views 154

Innovative Pathway Towards a Universal COVID-19 Vaccine In the wake of a global resurgence of COVID-19, Dx&Vx (DXVX) is stepping up its efforts to develop a universal vaccine aimed at providing protection against all variants of the virus. With the recent acquisition of cutting-edge technology, this next-generation vaccine is set to attract significant global interest....

Continue Reading